EUVIMEDEUVIMED entdecken
FallberichtStudienprotokollOpen Access

Novel desensitization protocol utilizing conventional formulations to mitigate Temozolomide-Related skin hypersensitivity

Morgan E Cantley, Clyde Coleman, Rachael M Morgan, Niharika Reddy, Sarah A Sertich, John L Villano

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04782-9 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Morgan E Cantley und 5 weiteren Autor:innen. Beteiligte Einrichtung: Markey Cancer Center, University of Kentucky, Lexington, KY, USA. Hauptthemen laut MEDLINE: Temozolomide, Antineoplastic Agents, Alkylating, Desensitization, Immunologic, Glioblastoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Temozolomide (TMZ) is an oral alkylating agent used in the first-line treatment regimen for glioblastoma (GBM) and other high-grade gliomas, with demonstrated improvement in survival outcomes. Dermatological hypersensitivity reactions are uncommon, however when severe can halt further use of TMZ. We describe a case of a 25-year-old female with GBM who developed recurrent cutaneous hypersensitivity reactions to TMZ, including diffuse urticarial lesions and pruritus. A rapid desensitization protocol using only commercially available TMZ capsules (5 mg, 20 mg, and 100 mg) was successfully implemented, enabling continuation of treatment without the need for complicated compounding or dilution. The desensitization protocol was initially administered in a monitored clinical setting and subsequently adapted for home use, improving feasibility and adherence. This case demonstrates that TMZ desensitization using standard dosage forms is a viable strategy to overcome hypersensitivity, allowing patients to maintain optimal GBM therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideAntineoplastic Agents, AlkylatingDesensitization, ImmunologicGlioblastomaDrug HypersensitivityDacarbazineHumansFemaleAdultBrain Neoplasms

Stichwörter der Autor:innen

DesensitizationDrug-induced reactionsGlioblastomaRashTemozolomide

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingDacarbazine

Autor:innen und Institutionen

  • Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
  • Department of Pharmacy Services, University of Kentucky, Lexington, KY, USA.
  • Division of Medical Oncology, Department of Internal Medicine, University of Kentucky, Lexington, KY, USA.
  • Markey Cancer Center, University of Kentucky, Lexington, KY, USA. jlvillano@uky.edu.
  • Division of Medical Oncology, Department of Internal Medicine, University of Kentucky, Lexington, KY, USA. jlvillano@uky.edu.
  • Department of Neurology, University of Kentucky, Lexington, KY, USA. jlvillano@uky.edu.

Förderung

  • NCI NIH HHS

Zitieren

APA

Cantley, M. E., Coleman, C., Morgan, R. M., Reddy, N., Sertich, S. A., & Villano, J. L. (2025). Novel desensitization protocol utilizing conventional formulations to mitigate Temozolomide-Related skin hypersensitivity. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04782-9

Vancouver

Cantley ME, Coleman C, Morgan RM, Reddy N, Sertich SA, Villano JL. Novel desensitization protocol utilizing conventional formulations to mitigate Temozolomide-Related skin hypersensitivity. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04782-9

BibTeX
@article{Cantley2025,
  author = {Cantley, Morgan E and Coleman, Clyde and Morgan, Rachael M and Reddy, Niharika and Sertich, Sarah A and Villano, John L},
  title = {Novel desensitization protocol utilizing conventional formulations to mitigate Temozolomide-Related skin hypersensitivity},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04782-9}
}
Kostenlos starten →